# US 2026/0125345 A1 · Salts and solid forms of n-ethyl-2-(5-fluoro-1h-indol-3-yl)-n-methylethan-1-amine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0125345 A1
- Document ID: US20260125345A1
- Status: Published application
- Kind: A1
- Application number: 19/427,136
- Filed: 2025-12-19
- Published: 2026-05-07
- Earliest claimed: 2022-01-27
- Applicants: Terran Biosciences Inc.
- Inventors: Matthew Duncton; Samuel Clark
- Web page: https://patentgrep.com/patent/US20260125345A1

## CPC

- C07D 209/16: Tryptamines
- A61K 31/36: Compounds containing methylenedioxyphenyl groups, e.g. sesamin
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- C07C 53/06: Salts thereof
- C07C 53/10: Salts thereof
- C07C 55/07: Salts thereof
- C07C 55/10: Succinic acid
- C07C 55/12: Glutaric acid
- C07C 55/14: Adipic acid
- C07C 55/20: Sebacic acid
- C07C 57/12: Straight chain carboxylic acids containing eighteen carbon atoms
- C07C 59/105: having five or more carbon atoms, e.g. aldonic acids
- C07C 59/245: containing hydroxy or O-metal groups
- C07C 59/265: Citric acid
- C07C 59/285: Polyhydroxy dicarboxylic acids having five or more carbon atoms, e.g. saccharic acids
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Disclosed herein are salt and solid forms of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine. The solid form may be a salt and/or a crystalline form of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine, such as a polymorph of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine or a salt thereof. Also disclosed are methods for making the salts and solid forms and methods for administering the same. The solid forms of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine are useful for treating neurological disease and/or a psychiatric disorder in a subject.

## Claims

### Claim at position 1

-42. (canceled)

### Claim 43

A crystalline N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine (compound 1) hydrochloride salt characterized by two or more XRPD signals selected from the group consisting of 25.1 °2θ, 16.5 °2θ, and 26.2 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu Kα1 radiation).

### Claim 44 (depends on 43)

The compound 1 hydrochloride salt of claim 43 characterized by XRPD signals at 25.1 °2θ, 16.5 °2θ, and 26.2 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu Kα1 radiation).

### Claim 45 (depends on 43)

The compound 1 hydrochloride salt of claim 43 characterized by XRPD signals at 25.1 °2θ, 16.5 °2θ, 26.2 °2θ, 15.1 °2θ, and 17.0 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu Kα1 radiation).

### Claim 46 (depends on 43)

The compound 1 hydrochloride salt of claim 43 characterized by XRPD signals at 25.1 °2θ, 16.5 °2θ, 26.2 °2θ, 15.1 °2θ, 17.0 °2θ, 11.0 °2θ, and 27.8 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu Kα1 radiation).

### Claim 47 (depends on 43)

The compound 1 hydrochloride salt of claim 43 characterized by XRPD signals at 25.1 °2θ, 16.5 °2θ, 26.2 °2θ, 15.1 °2θ, 17.0 °2θ, 11.0 °2θ, 27.8 °2θ, 27.2 °2θ, 31.0 °2θ, and 26.8 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu Kα1 radiation).

### Claim 48 (depends on 43)

The compound 1 hydrochloride salt of claim 43 characterized by any combination of the XRPD signals in Table 1A.

### Claim 49 (depends on 43)

The compound 1 hydrochloride salt of claim 43 characterized by a XRPD diffractogram substantially similar to that shown in FIG. 1.
